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Introduction Clinical Materials 
The most feared complication after aortic reconstruc- 
tion is infection, principally because the ensuing death 
and/or amputation rate may exceed 70%. 1 Its relative 
rarity (1-2%) 1' 2 has contributed towards problems in 
determining the optimal mode of management 
because thousands of patients would be required in 
prospective trials to prove the effectiveness of one 
treatment regime over another. Accordingly the lit- 
erature contains genuine claims and counter-claims on
the respective merits of antibiotic irrigation, total graft 
excision, extra-anatomical bypass, autologous recon- 
struction, in situ prosthetic revascularisation r retro- 
peritoneal in-line prosthetic bypass. 3-7 
Until recently, it had been our policy to excise 
infected aortic prostheses and undertake synchronous 
extra-anatomic bypass. However we were then faced 
with a patient with an infected aortic graft, massive 
retroperitoneal abscess formation and poor peripheral 
perfusion in whom flexion deformities at the hips 
precluded extra-anatomical bypass. We therefore 
undertook to manage this patient by graft excision 
and in situ replacement with a rifampicin bonded 
prosthesis as had been recently advocated by Stra- 
chan. 8 Impressed with the outcome, we have since 
dealt with four further patients in a similar manner. 
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Patients were commenced on parenteral antibiotics 
(cefuroxime and metronidazole) once the diagnosis of 
graft infection was suspected and each received a 
further bolus with induction of anaesthesia. Preopera- 
ive CT scans and angiograms were performed rou- 
tinely unless clinical urgency precluded them. At the 
time of undertaking this study there were no MRI 
facilities at this hospital. At operation, the aorto-iliac 
segments were mobilised and any macroscopically 
infected tissue debrided. The original graft was then 
excised and replaced with a rifampicin-bonded pros- 
thesis in the manner described by Strachan. 8 In 
summary, a 20ml ampoule containing 600mg of 
rifampicin (Merrell Dow) was reconstituted with 10ml 
of solvent provided. The resultant solution was added 
to a kidney dish into which was placed a pre-prepared 
and sized gelatin impregnated, knitted Dacron graft 
(Gelsoft, Vascutek Ltd, UK) and lavaged for ten 
minutes in order to ensure complete bonding of the 
antibiotic to the gelatin coating. The prosthesis was 
then anastomosed in the standard manner and cov- 
ered with an omental pedicle where possible. Post- 
operatively, all patients were continued on parenteral 
and then oral antibiotics (usually cefuroxime or 
ciprofloxacillin and metronidazole) for 6 weeks. The 
exact choice depended on micro-organism sensitivities 
and patient allergies. The decision to stop antibiotic 
therapy at 6 weeks was based on pre-existing unit 
policy when all patients had been reviewed and there 
was no clinical evidence of residual infection. In 
additiqn, each patient underwent a III Indium labelled 
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white cell scan 3 to 6 months after surgery in order to 
exclude occult, residual infection. 9 
Case 1 
A 67-year-old male with rheumatoid arthritis under- 
went elective repair of an infrarenal abdominal aortic 
aneurysm (AAA) using woven Dacron under systemic 
antibiotic over (cefuroxime) in 1986. Five years later, 
he presented with pyrexia and increasing left sided 
abdominal pain radiating down the left leg. On 
examination he had a tender, left sided abdominal 
mass and a low grade pyrexia. There were flexion 
deformities at both hips and distal imb perfusion was 
poor. ACT  scan revealed a large retroperitoneal 
abscess and an angiogram demonstrated a false 
aneurysm at the proximal anastomosis. A large 
abscess (yielding Streptococcus viridans) and false 
aneurysm were confirmed at laparotomy. The aortic 
graft was excised and replaced with a rifampicin 
bonded prosthesis. In addition, two foley catheters 
were positioned in the retroperitoneal space and 
irrigated every 8 hours with gentamicin solution. 
Irrigations were continued for 2 weeks, when there 
was resistance to fluid passage, and the catheters 
removed. Systemic and then oral antibiotics were 
continued for 6 weeks postoperatively. To date, he has 
remained asymptomatic for 24 months with no evi- 
dence of recurrence of sepsis. An Indium labelled 
white cell scan at 6 months showed no evidence of 
residual infection. 
Case 2 
A 75-year-old male underwent aortobi-iliac repair of 
an infrarenal AAA using woven Dacron under sys- 
temic antibiotic over (cefuroxime) in 1990. Because of 
subsequent poor limb perfusion, an extension was 
taken from the right graft limb to the ipsilateral 
femoral artery. Fifteen months later, he presented with 
a right ileo-femoral graft limb occlusion and angiog- 
raphy revealed a false aneurysm at the junction of the 
iliac anastomoses on the right. At operation, the false 
aneurysm was confirmed and culture yielded Escher- 
ischia coli. The grafts were excised and an in situ 
rifampicin bonded prosthesis inserted. Systemic and 
then oral antibiotics were continued for 6 weeks after 
surgery. His postoperative course was uncomplicated 
and he has remained asymptomatic for 15 months. An 
Indium labelled white cell scan four months after 
surgery showed no evidence of residual infection. 
Case 3 
A 68-year-old female underwent aortobifemoral 
bypass for occlusive disease using woven Dacron 
under systemic antibiotic over (cefuroxime) in 1992. 
Four months later she presented with a groin abscess 
(culturing Streptococcus faecalis) and a CT scan 
revealed an abdominal peri-graft collection. She was 
treated by total graft excision with in situ replacement 
with a rifampicin bonded prosthesis. Systemic and 
then oral antibiotics were continued for six weeks 
after surgery. There were no postoperative complica- 
tions and she has remained asymptomatic for 12 
months. An Indium labelled white cell scan 4 months 
after operation showed no evidence of residual 
infection. 
Case 4 
A 49-year-old male underwent repair of an infrarenal 
AAA using woven Dacron to the common iliac 
arteries under systemic antibiotic over (cefuroxime) 
in 1988. Sixty-four months later, he presented with 
haematemesis and melaena. Endoscopy of the upper 
gastrointestinal tract was normal. At operation, he was 
found to have an aorto-jejunal fistula arising from a 
false aneurysm at the proximal anastomosis. Culture 
of the aortic wall and anastomosis yielded S. albus, S. 
milleri and Haemophilus parainfluenzae. The defect in 
the jejunum was repaired, the graft excised and 
replaced with a rifampicin bonded bifurcated prosthe- 
sis. Two foley catheters were positioned in the 
retroperitoneal space deep to the omental pedicle. 
Irrigations were performed every 8 hours using 
augmentin for 2 weeks by which time there was 
resistance to irrigation and the catheters were 
removed. During this time he had a prolonged ileus 
and required parenteral nutrition. Systemic and then 
oral antibiotics were continued for 6 weeks after 
surgery. To date he has remained asymptomatic for 6 
months and an Indium labelled white cell scan 4 
months after surgery showed no evidence of residual 
infection. 
Case 5 
A 65-year-old male underwent repair of an infrarenal 
AAA with woven Dacron under systemic antibiotic 
cover (cefuroxime and metronidazole) in 1992. Five 
months later, he presented with increasing back pain 
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Table 1. Management options in major aortic graft infection 
(i) No graft excision 
+ systemic antibiotics 
+ retroperitoneal debridement and antibiotic rrigation 
(ii) Total graft excision (TGE) 
+ "extra-anatomical" v scular reconstruction 
TGE preceded by axillofemoral bypass 
TGE + synchronous axillofemoral bypass 
TGE + delayed axillofemoral bypass (i.e. if required) 
+ "anatomical" vascular reconstruction 
TGE + autologous reconstruction using native artery or vein 
TGE + in-line replacement with prosthesis (no antibiotic bonding) 
TGE + in situ replacement with allograft 
TGE + in situ replacement with prosthesis (no antibiotic bonding) 
TGE + in situ replacement with prosthesis +gentamicin beads/sponge 
TGE + in situ replacement with antibiotic bonded prosthesis 
and collapse. An ultrasound scan suggested rupture of 
a false aneurysm above the proximal anastomosis. At 
operation, a large ruptured false aneurysm cavity was 
found to involve the proximal anastomosis and supra- 
renal aorta. In addition, the anterior aspect of the 
thoracic vertebrae adjacent to the false aneurysm were 
eroded. Subsequent culture of the sac contents yielded 
S. albus. The aorta was cross-clamped at the dia- 
phragm and the suprarenal aorta and graft exposed by 
reflecting the left colon, kidney and spleen medially. 
After removal of the graft, a rifampicin bonded 
prosthesis was anastomosed end-to-end to the prox- 
imal aorta preserving the origin of the coeliac axis. The 
superior mesenteric and both renal arteries were then 
reimplanted onto the graft. Postoperatively he 
received parenteral and then oral antibiotics for six 
weeks. He suffered no major postoperative complica- 
tions and although his renal function was transiently 
impaired, he did not require dialysis. To date he has 
remained asymptomatic for 4 months and his back 
pain has resolved. An Indium labelled white cell scan 
3 months after surgery showed no evidence of 
residual infection. 
Discussion 
Major aortic graft infection (MAGI), affecting the 
proximal anastomosis and/or main body of graft, is 
fortunately rare, individual experience relatively lim- 
ited and consequently, there are many opinions on 
optimal management. Three important principles dic- 
tate current attitudes to treatment: (i) eradication of 
infection; (ii) ensuring adequate peripheral perfusion; 
and (iii) minimising mortality and morbidity. The 
ultimate choice of intervention is therefore always 
going to be a compromise between idealism and 
reality, and has to be based on urgency of presentation, 
patient fitness, type of previous surgery and likely 
outcome. 
Table 1 summarises current management options 
in MAGI. Partial graft excision is not included as the 
authors believe that this option should really only be 
considered in those with limited aortofemoral graft 
limb infections (which are difficult to diagnose preop- 
eratively). The mortality with non-surgical inter- 
vention in MAGI approaches 100% l° and no-one 
currently advocates this as a definitive treatment. 
However, Quick et al. 3 have recently treated four 
patients with MAGI (three successfully) by retro- 
peritoneal debridement and postoperative antibiotic 
irrigation. One patient suffered a fatal reinfection after 
42 months. We used adjunctive postoperative r tro- 
peritoneal antibiotic irrigation in two of our patients 
and feel that it probably contributed to the overall 
success. However, as with Quick, we noted abdominal 
discomfort, prolonged ileus and wound leaks to be 
problems. It remains to be seen whether further 
experience confirms similar results, the main con- 
ceptual problem being whether the irrigant can 
eradicate all foci of infection from all of the graft. 
It is likely however that most surgeons, when 
faced with MAGI, will undertake TGE and debride- 
ment of local tissues as the major definitive treatment. 
While this undoubtedly contributes towards eradicat- 
ing the source of infection, it inevitably makes the 
procedure more complex and increases mortality and 
morbidity. TGE is usually combined with either extra- 
anatomical or in situ lower limb revascularisation in 
order to preserve gluteal and lower limb perfusion 
and thus lessen the risk of amputation. Extra-anatomi- 
cal bypass, usually axillo(bi)femoral, is a relatively 
straightforward procedure but is associated with 
important problems: (i) aortic stump blowout which is 
usually fatal; 11 (ii) thrombus formation in the aortic 
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stump which may compromise r nal artery flow; 12 (iii) 
axillofemoral bypass has a significantly lower long- 
term patency than aortofemoral bypass and hence the 
risks of ischaemia, thrombectomy and amputation are 
cumulatively higher; (iv) gluteal ischaemia is more 
likely with axillofemoral as opposed to aortofemoral 
reconstruction; (v) the axiltofemoral grafts are still 
liable to re-infection. The relative risks of each of these 
problems can be modified 4 by: (i) inserting the 
axillofemoral bypass prior to TGE (i.e. patient gen- 
erally titter, limb perfusion maintained but suffering 
risks of two operations with a slightly higher risk of 
re-infection); (ii) synchronous TGE and axillofemoral 
bypass (i.e. one long operation and increased blood 
loss and probably mortality though limb perfusion is 
maintained); or (iii) TGE with delayed axillofemoral 
bypass if required. The latter is rarely recommended 
because of the considerable risk of limb ischaemia, 
amputation and the prospect of a rapidly deteriorat- 
ing patient. Overall, TGE with axillofemoral bypass 
carries a mortality rate of 10--40%, 4'12 but occasionally 
70%, 13 a 20% risk of aortic stump blow-out, 12'13 a 
15--40% risk of re-infection, 4 axillofemoral graft failure 
(infection/occlusion) i  up to 50% 14 and an amputa- 
tion rate of 20-50%.2' 4Our o*wn personal experience is 
somewhat similar. In the seven years prior to using in 
situ rifampicin bonded grafts, twelve MAGI's were 
treated in Leicester by TGE and axillofemoral bypass. 
Six (50%) died within 30 days and four (25%) required 
a major limb amputation. 
The alternative to extra-anatomical bypass after 
TGE is revascularisation f the lower limbs through 
using autogenous tissues, in situ or retroperitoneal 
bypass. Autogenous reconstructive methods have the 
advantage ofavoiding prosthetic material and include 
closure of the aortic stump with a vein patch, bringing 
two saphenous vein grafts distally from incisions in 
the patch, 5 though in Lorentzen's eries of eight 
patients, 5 only two avoided death, amputation or 
major graft related complications. Other autogenous 
alternatives 4 include graft excision with native vessel 
endarterectomy (no use if the original pathology was 
aneurysm and relatively few surgeons have expertise 
in this technique) or vein patch angioplasty (only 
possible in patients with end-to side anastomoses). 
Thus, despite the attractive potential, the results o far 
and likelihood of exclusions mean that autogenous 
reconstruction is unlikely to become widely 
applicable. 
Leather et al. 6 have proposed a compromise 
between extra-anatomical and in situ reconstruction 
after total graft excision. In their method, the non- 
infected aorta is mobilised proximally and distally (via 
an extra-peritoneal approach) and a PTFE graft tun- 
nelled through non-infected retroperitoneal tissues. 
Thereafter the original graft is removed through a 
transperitoneal pproach. Using this technique in 
seven patients they have achieved complete healing 
with no loss of life or limb. However, they do concede 
that problems may present with ensuring absence of 
infection in the tissue planes of the retroperitoneum or 
aorta and reconstruction adjacent to the renal 
arteries. 6 
The final alternative is TGE and in situ revascular- 
isation using prosthetic material. The success of 
unprotected grafts depends on there being no overt 
residual infection and low virulence organisms. 1 In 
Jacobs' series, 7no deaths or amputations occurred in 
12 patients undergoing in situ reconstruction in whom 
blood and peri-graft cultures were negative. However 
five of six patients died where cultures were positive. 
In Walker's series, 15 43% of patients had early or late 
graft related complications or mortality including an 
early mortality of 22%, 8% had a protracted hospital 
stay, 8% died within 3 months because of proximal 
anastomotic rupture and 4% had to have repair of a 
proximal false aneurysm. In our opinion, there is now 
no indication to use an unprotected graft in the in situ 
position given the results obtained using antibiotic 
bonded grafts. 
The principal advantages of replacing an infected 
graft with an antibiotic bonded prosthesis combine 
those of the in situ approach (use of anatomical 
pathway, better patency) with the potential benefits of 
locally high concentrations of antibiotic to reduce the 
risks of ongoing infection. Early antibiotic protected 
prostheses were unsuccessful, argely because the 
antimicrobial was washed out too quickly, s' 16 Thus 
there must be some vehicle for bonding (e.g. gelatin, 
collagen or albumin) which then enables low release 
of the antibiotic into the graft interstices for up to three 
weeks.S, 16,17 Animal studies suggest hat antimicro- 
bial bonded grafts do not interfere with healing or 
formation of the pseudo-intima is and when inserted 
prior to a challenge with S. aureus, are associated with 
significantly fewer graft infections than normal 
grafts. 19 Rifampicin might be considered an unusual 
choice of antibiotic, but it has good anti-staphyloccal 
activity,8,17 including slime forming and multi-resis- 
tant varieties and it is not in regular use elsewhere in 
vascular surgery. 8 
In this series, we were forced into in situ replace- 
ment in two patients, one because of potential difficul- 
ties in exposing the femoral arteries and one because 
the infective process involved the suprarenal aorta 
and visceral arteries. To date we have had no Indium 
labelled white cell scan evidence of recurrent infec- 
tion, although we accept that longer follow-up is 
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required. However we have been impressed so far 
with the zero mortality and limb loss. Torsello et al. 
have also recently reported their experience of rifam- 
picin bonded grafts in the treatment of five patients 
with MAGI, including one patient with visceral artery 
involvement. 2°As with our experience, none died, no- 
one required a major limb amputation and none have 
had any evidence of re-infection on postoperative CT 
scanning. 
In conclusion, recent experience with TGE and in 
situ replacement with a rifampicin bonded prosthesis 
shows considerable potential and should be con- 
sidered as an alternative to the more traditional 
approaches when managing major aortic graft 
infection. 
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